Eisai R&d Management Co., Ltd.

Michael W Seiler

Ping Zhu

Silvia Buonamici

Lihua Yu

Peter G Smith

Ermira Pazolli

James Palacino

Dominic J Reynolds

Nathan Elliott Fishkin

Andrew Cook

Sudeep Prajapati

Xiang Liu

Shelby Ellery

Thiwanka Samarakoon

Megan Sheehan

Zhenhua Wu

Nicholas Calandra

Yonghong Xiao

Yoshiharu Mizui

Kian Huat Lim

Eunice Sun Park

Jacob D Feala

Marco Peter Fekkes

Shouyong Peng

Evan Barry

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Splicing modulator antibody-drug conjugates and methods of use

This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Methods of using splicing modulators

Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.

Splice variants associated with neomorphic SF3B1 mutants

Growing community of inventors

Watertown, MA, United States of America

Michael W Seiler